Previous Close | 13.36 |
Open | 13.37 |
Bid | 0.00 x 4000 |
Ask | 0.00 x 2900 |
Day's Range | 13.30 - 13.41 |
52 Week Range | 13.11 - 17.11 |
Volume | |
Avg. Volume | 1,837,083 |
Market Cap | 41.984B |
Beta (5Y Monthly) | 0.54 |
PE Ratio (TTM) | 37.17 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 0.64 (4.77%) |
Ex-Dividend Date | Sept 28, 2023 |
1y Target Est | N/A |
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced positive topline data for its Phase 2 SAVITRI™ study. This randomized, double-blind, placebo-controlled dose-finding study assessed the efficacy and safety of NBI-1065845 in adult subjects with major depressive disorder (MDD). NBI-1065845 is an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) positive allosteric modulator (PAM) in development as a potential treatment for patients with MDD who have not be
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK, President and CEO; Christophe Weber, "Takeda"), Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), and Sumitomo Mitsui Banking Corporation (President & CEO: Akihiro Fukutome, "SMBC") today announced that the three companies signed a master agreement on April 22, 2024, to establish a joint venture company. The new company will be dedicated to the incubation*1 of early drug discovery programs, primarily origin
OSAKA, Japan & CAMBRIDGE, Mass., April 18, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn’s disease (CD) after induction therapy with intravenous (IV) ENTYVIO.1 The subcutaneous administration of ENTYVIO was also approved by FDA in September 2023 for the maintenance treatment of adults with moderately to